SEC Form 4 · accession 0000899243-19-000995
Zymeworks Inc. · ZYME
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Diana Hausman
Officer — Chief Medical Officer
Period of report
Jan 8, 2019
Accepted (ET)
Jan 10, 2019 · 5:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403752
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jan 8, 2019 | A | 499 | $12.48 | A | 2,499 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $15.53 | Jan 8, 2019 | A | 75,000 | A | — | Jan 7, 2029 | Common Shares | 75,000 | 75,000 | D |
Explanation of responses
- F1Shares purchased pursuant to the issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2018 through December 31, 2018. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the issuer's common shares on December 31, 2018.
- F2Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.